TGA / PMDA / NMPA · Asia-Pacific
t-cell — TGA / PMDA / NMPA regulatory status
t-cell regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 229 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| CADET-PAD | Phase 3 | COLLEGIUM PHARMACEUTICAL | 2024-511894-32-00 |
| CAIN457R12301 | Phase 3 | Novartis India | 2024-510744-31-00 |
| CAIN457R1DE01 | Phase 3 | Novartis India | 2024-512856-40-00 |
| DCC-3014-03-001 | Phase 3 | Anaxis Pharma | 2024-513624-42-00 |
| E7777 9 mcg/kg | Phase 3 | CITIUS ONCOLOGY | NCT01871727 |
| M16-852 | Phase 3 | AbbVie Deutschland GmbH | 2023-505476-29-00 |
| Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） | Phase 3 | Chinese Academy of | NCT06041061 |
| SBI-0145-304 | Phase 3 | Secura Bio | 2024-516605-23-00 |
| SPI-BEL-301 | Phase 3 | Anaxis Pharma | 2023-507803-76-00 |
| Sarilumab SAR153191 | Phase 3 | Regeneron UK | NCT03600805 |
| Soquelitinib | Phase 3 | Corvus Pharmaceuticals | NCT06561048 |
| TOCILIZUMAB, Placebo of Tocilizumab | Phase 3 | PARItec | 2024-511906-21-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12421287 | T-cell modulatory multimeric polypeptides and methods of use thereof | US |
| 12421302 | CAR-t cells and autoimmune diseases | US |
| 2025290040 | GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE | US |
| 12415843 | Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer | US |
| 12404317 | T cell receptors recognizing MHC class II-restricted MAGE-A3 | US |
| 12391742 | Anti-KRAS-G12D T cell receptors | US |
| 12391739 | Method for producing gamma delta T cells | US |
| 12391741 | T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof | US |
| 12384817 | Peptide having protective activity against cell damage caused by particulate matter, and uses for same | US |
| 12370256 | Activation of resident memory T cells for the treatment of cancer | US |
| 12358968 | Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer | US |
| 12344654 | Mage A4 T cell receptors | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of t-cell?
t-cell currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get t-cell regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to t-cell?
This spoke lists 229 published programs associated with t-cell in our pipeline index.